CO4790092A1 - GRANISETRON FOR DIARRHEA TREATMENT - Google Patents
GRANISETRON FOR DIARRHEA TREATMENTInfo
- Publication number
- CO4790092A1 CO4790092A1 CO97015009A CO97015009A CO4790092A1 CO 4790092 A1 CO4790092 A1 CO 4790092A1 CO 97015009 A CO97015009 A CO 97015009A CO 97015009 A CO97015009 A CO 97015009A CO 4790092 A1 CO4790092 A1 CO 4790092A1
- Authority
- CO
- Colombia
- Prior art keywords
- granisetron
- diarrhea
- composition according
- treatment
- prophylaxis
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract 6
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 title abstract 6
- 229960003727 granisetron Drugs 0.000 title abstract 6
- 238000011282 treatment Methods 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 4
- 238000011321 prophylaxis Methods 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 210000004877 mucosa Anatomy 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010007270 Carcinoid syndrome Diseases 0.000 abstract 1
- 206010008631 Cholera Diseases 0.000 abstract 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000008752 local inflammatory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de granisetron en la fabricación de un medicamento para el tratamiento o la profilaxis de diarrea. Un método de tratamiento o profilaxis de diarrea en animales mamíferos, incluyendo el hombre, que comprende administrar granisetron al animal mamífero en necesidad de ello. Una composición farmacéutica para uso en el tratamiento y/o la profilaxis de diarrea, que comprende granisetron y un vehículo farmacéuticamente aceptable. Un uso, un método o una composición según la reivindicación 1, 2 o 3, en el que la diarrea está asociada con procesos HIV-positivos o SIDA y con otras enfermedades inmunodeficientes, especialmente aquellas que comprometen la integridad de la mucosa gastrointestinal y/o procesos inflamatorios locales de las mucosas, síndrome carcinoide y otros tumores gastrointestinales y también con regímenes de tratamiento contra el cáncer. Un uso, un método o una composición según la reivindicación 1, 2 ó 3, en el que la diarrea está asociada con cólera. Un uso, un método o una composición según una cualquiera de las reivindicaciones 1 a 5, en el que el granisetron se administra intravenosamente. Un uso, un método o una composición según una cualquiera de las reivindicaciones 1 a 5, en el que el granisetron se administra oralmente.The use of granisetron in the manufacture of a medicine for the treatment or prophylaxis of diarrhea. A method of treatment or prophylaxis of diarrhea in mammalian animals, including man, comprising administering granisetron to the mammalian animal in need thereof. A pharmaceutical composition for use in the treatment and / or prophylaxis of diarrhea, comprising granisetron and a pharmaceutically acceptable carrier. A use, method or composition according to claim 1, 2 or 3, in which diarrhea is associated with HIV-positive processes or AIDS and with other immunodeficient diseases, especially those that compromise the integrity of the gastrointestinal mucosa and / or local inflammatory processes of the mucosa, carcinoid syndrome and other gastrointestinal tumors and also with cancer treatment regimens. A use, method or composition according to claim 1, 2 or 3, wherein the diarrhea is associated with cholera. A use, method or composition according to any one of claims 1 to 5, wherein the granisetron is administered intravenously. A use, method or composition according to any one of claims 1 to 5, wherein the granisetron is administered orally.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9606745.9A GB9606745D0 (en) | 1996-03-29 | 1996-03-29 | Pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4790092A1 true CO4790092A1 (en) | 1999-05-31 |
Family
ID=10791339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97015009A CO4790092A1 (en) | 1996-03-29 | 1997-03-20 | GRANISETRON FOR DIARRHEA TREATMENT |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR006437A1 (en) |
| AU (1) | AU2290597A (en) |
| CO (1) | CO4790092A1 (en) |
| GB (1) | GB9606745D0 (en) |
| WO (1) | WO1997036586A1 (en) |
| ZA (1) | ZA972684B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000048597A1 (en) | 1999-02-18 | 2000-08-24 | Novartis Ag | Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes |
-
1996
- 1996-03-29 GB GBGB9606745.9A patent/GB9606745D0/en active Pending
-
1997
- 1997-03-20 CO CO97015009A patent/CO4790092A1/en unknown
- 1997-03-20 AU AU22905/97A patent/AU2290597A/en not_active Abandoned
- 1997-03-20 WO PCT/EP1997/001463 patent/WO1997036586A1/en active Application Filing
- 1997-03-26 AR ARP970101255A patent/AR006437A1/en not_active Application Discontinuation
- 1997-03-27 ZA ZA972684A patent/ZA972684B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR006437A1 (en) | 1999-08-25 |
| AU2290597A (en) | 1997-10-22 |
| ZA972684B (en) | 1998-09-28 |
| GB9606745D0 (en) | 1996-06-05 |
| WO1997036586A1 (en) | 1997-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020015A1 (en) | CELECOXIB COMPOSITIONS | |
| ES2177780T3 (en) | MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING INTERFERON TAU. | |
| AR013506A1 (en) | USE OF A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO BE USED IN THE TREATMENT OF DISEASES OF PULMONARCHRONIC OBSTRUCTION AND OF A KIT INCLUDING FORMOTEROL OR A SALT OR SOLVATE OF THE SAME AND BUDESONIDE | |
| AR012614A1 (en) | A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A SUSCEPTIBLE VIRAL INFECTION OF TREATMENT WITH ALPHA INTERFER, A METHOD FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, FOR THE MANUFACTURE OF A MEDICINE | |
| ES2139132T3 (en) | PHARMACEUTICAL COMPOSITIONS ACTIVE IN SLEEP DISORDERS THERAPY. | |
| ES2069582T3 (en) | THERAPEUTIC NUCLEOSIDES. | |
| ATE125445T1 (en) | ORAL COMPOSITION FOR THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES. | |
| IT1253711B (en) | VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| MY107843A (en) | Anti-viral compounds. | |
| NO179582C (en) | Analogous Process for Preparing Therapeutically Active Hydroxamic Acid and N-Hydroxyurea Derivatives | |
| FI974385A0 (en) | Preparation of xylitol For the purpose of pharmaceutical treatment and xylitol preparations For the manufacture of xylitol | |
| NO173998C (en) | Analogous Procedures for Preparing Therapeutically Active Benzimidazole Derivatives | |
| AR004510A1 (en) | COMPOSITIONS INCLUDING AMOXICILLIN AND CLAVULANATE, PROCEDURES FOR ITS PREPARATION AND THE USE OF COMPOSITIONS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| BR0109672A (en) | Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal | |
| MX173567B (en) | PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION | |
| AR008886A1 (en) | USE OF AN H +, K + -ATPASE INHIBITOR IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NASAL POLIPS, OF THE WIDAL SYNDROME, USE OF SUCH INHIBITOR AND A GLUCOCORTICOID FOR THE MANUFACTURE OF A PHARMACEUTICAL FORMULATION AND PHARMACEUTICAL FORMULATION | |
| TR200400228T4 (en) | Substances used in the treatment of psoriasis | |
| ATE82294T1 (en) | THERAPEUTIC NUCLEOSIDES. | |
| MX9205568A (en) | PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE. | |
| ES2108130T3 (en) | IMPROVED PHARMACOLOGICAL FORMULATIONS. | |
| NO306762B1 (en) | Use of lanolin derivatives in conjunction with polyethylene glycol ethers, their mixture and transdermal therapeutic system | |
| ES2153842T3 (en) | DERIVATIVES OF 3-OXO-PIRIDO (1,2-A-) BENCIMIDAZOL-4-CARBOXYL AND 4-OXO-AZEPINO (1,2-A) BENCIMIDAZOL-5-CARBOXYL USEFUL IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM. | |
| YU44392A (en) | PROCEDURE FOR PREPARATION OF PHARMACEUTICAL FORMULATION OF DIRITROMYCIN | |
| CO4790092A1 (en) | GRANISETRON FOR DIARRHEA TREATMENT | |
| HUP9901659A2 (en) | Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system |